Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, S. -R.
Right arrow Articles by Wang, S. -J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, S. -R.
Right arrow Articles by Wang, S. -J.
Related Collections
Right arrow All Headache
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;62:1414-1416
© 2004 American Academy of Neurology
Brief Communications

Nimodipine for treatment of primary thunderclap headache

S. -R. Lu, MD, Y. -C. Liao, MD, J. -L. Fuh, MD, J. -F. Lirng, MD and S. -J. Wang, MD

From the Department of Neurology (Dr. Lu), Kaohsiung Medical University, Chung-Ho Memorial Hospital, Neurological Institute (Drs. Liao, Fuh, and Wang) and Department of Radiology (Dr. Lirng), Taipei Veterans General Hospital, and National Yang-Ming University School of Medicine (Drs. Liao, Fuh, Lirng, and Wang), Taiwan.

Address correspondence and reprint requests to Dr. S.-J. Wang, Neurological Institute, Taipei Veterans General Hospital, Taipei, 11217, Taiwan; e-mail: sjwang{at}vghtpe.gov.tw

Eleven patients with primary thunderclap headache (TCH) were treated with oral nimodipine 30 to 60 mg every 4 hours or IV nimodipine 0.5 to 2 mg/h if the oral regimen failed or images showed cerebral vasospasm. With oral nimodipine, headache did not recur in the nine patients without vasospasm. IV nimodipine was given in two patients with vasospasm, including one who developed ischemic stroke. Nimodipine may be effective for TCH. Vasospasm may warrant IV nimodipine.

Received October 17, 2003. Accepted in final form December 16, 2003.




This article has been cited by other articles:


Home page
 BrainHome page
A. Ducros, M. Boukobza, R. Porcher, M. Sarov, D. Valade, and M.-G. Bousser
The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients
Brain, December 1, 2007; 130(12): 3091 - 3101.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
L. H. Calabrese, D. W. Dodick, T. J. Schwedt, and A. B. Singhal
Narrative Review: Reversible Cerebral Vasoconstriction Syndromes
Ann Intern Med, January 2, 2007; 146(1): 34 - 44.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. -P. Chen, J. -L. Fuh, J. -F. Lirng, F. -C. Chang, and S. -J. Wang
Recurrent primary thunderclap headache and benign CNS angiopathy: Spectra of the same disorder?
Neurology, December 26, 2006; 67(12): 2164 - 2169.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.